(redirected from Glycogen Synthase Kinase)
GSKGlaxoSmithKline plc (pharmaceutical company)
GSKGlycogen Synthase Kinase
GSKGlobal Security Kit
GSKGlobal Storage Key
GSKGursharan Singh Kohli (Ukranian production company)
GSKGruppentraining Sozialer Kompetenzen (Germany)
GSKGeneral Storekeeper (US Navy)
GSKGreenland Shark (FAO fish species code)
GSKGassner Stockmann Kollegen (law firm; various locations)
GSKGeneralized Shannon-Khinchin's Axiom
GSKGraveyard Shift Killers (Counter Strike clan)
GSKGod Save the King
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Ray, "Glycogen synthase kinase 3: more than a namesake," British Journal of Pharmacology, vol.
Dalton, "Subcellular localization of glycogen synthase kinase 3beta controls embryonic stem cell self-renewal," Molecular and Cellular Biology, vol.
Moon, "The axis-inducing activity, stability, and subcellular distribution of [beta]-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3," Genes and Development, vol.
Martinez, "The potential role of glycogen synthase kinase 3 inhibitors as Amyotrophic lateral sclerosis pharmacological therapy," Current Medicinal Chemistry, vol.
Abbreviations: HFD, high-fat diet; 2-NBDG, 2-(N-(7-nitrobenz-2-oxa-1, 3-diazol- 4-yl) amino)-2-deoxyglucose; AMPK, AMP-activated protein kinase; AKT/PKB, protein kinase B; AS160, Akt substrate of 160 kDa; GLUT1, translocation of glucose transporter 1; IRS-1, insulin receptor substrate; LKB1, liver kinase B1; GSK- 3[beta], glycogen synthase kinase 3[beta]; FoxO1, forkhead box O1; G6Pase, glucose-6- phosphatase; PEPCK, phosphoenolpyruvate carboxykinase; IR, insulin resistance; HepG2, hepatocellular carcinoma cell line.
(2002) Glycogen synthase kinase 3/SHAGGY-like kinases in plants: an emerging family with novel functions.
Paudel, "Glycogen synthase kinase 3[beta] phosphorylates Alzheimer's disease-specific Ser396 of microtubuleassociated protein tau by a sequential mechanism," Biochemistry, vol.
Chikano et al., "Aberrant glycogen synthase kinase 3[beta] is involved in pancreatic cancer cell invasion and resistance to therapy," Plos One, vol.
* Aripiprazole inhibits glutamate-induced neurotoxicity and, in contrast to haloperidol, increases BDNF, glycogen synthase kinase (GSK)-1[beta], and the anti-apoptotic protein Bc1-2.
Numerous kinases can phosphorylate tau, including cyclin-dependent kinases [37], glycogen synthase kinase 3 (GSK3) [38], microtubule affinity regulating kinase (MARK) [39], [Ca.sup.2+]/calmodulin-dependent protein kinase II (CaMKII) [40], protein kinase A (PKA) [41], and members of the mitogen activated protein kinase (MAPK) family including ERK2 [39] and c-jun N-terminal kinase (JNK) [26, 27].
By blocking the so-called SMAD signaling pathway and inhibiting glycogen synthase kinase 3 beta (GSK3B), they increased the transformational efficiency by several times--and were thus able to even simplify the means of extraction.
[5] Nonstandard abbreviations: miRNA or miR, microRNA; 3'-UTR, 3'-untranslated region; HIF, hypoxia-inducible factor; AR, androgen receptor; PI3K/Akt, phosphatidylinositol 3-kinase/RAC-alpha serine/threonine-protein kinase; CDK1B, cyclin-dependent kinase inhibitor 1B; GSK3B, glycogen synthase kinase 3 beta; PTEN, phosphatase and tensin homolog; PSA, prostate-specific antigen; VHL, von Hippel-Lindau tumor suppressor; HIF1A, hypoxia inducible factor 1; VEGF, vascular endothelial growth factor; FGFR3, fibroblast growth factor receptor 3.
Full browser ?